DSpace JSPUI
DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets
Learn More
Please use this identifier to cite or link to this item:
http://repo.tma.uz/xmlui/handle/1/2635| Title: | NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES |
| Authors: | Javohir Mullokulov., Khalmurad Akhmedov |
| Keywords: | To evaluate the clinical efficacy and cytokine-modulating effects of Iguratimod 25 mg in patients with Reactive |
| Issue Date: | 2025 |
| Citation: | Toshkent |
| Abstract: | Reactive Arthritis (ReA) is an immune-mediated form of spondyloarthritis, often triggered by genitourinary or gastrointestinal infections. Current therapeutic strategies rely mainly on NSAIDs and cs-DMARDs, with biologics reserved for refractory disease. However, limited progress has been made in exploring novel targeted agents. Iguratimod 25 mg, an oral immunomodulatory drug approved for rheumatoid arthritis in Asia, has demonstrated anti-inflammatory and cytokine-suppressive properties, but evidence in ReA is scarce |
| URI: | http://repo.tma.uz/xmlui/handle/1/2635 |
| Appears in Collections: | Articles |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| TermezConference.pdf | NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES | 919.61 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.